🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 13 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
18/07/2022 29,37 29,65 27,48 27,74 -4,48% 7,39% 796.400
15/07/2022 30,02 30,36 28,70 29,04 -1,69% 5,53% 653.900
14/07/2022 29,88 30,28 29,01 29,54 -1,76% 4,25% 485.400
13/07/2022 27,16 30,57 27,16 30,07 +7,55% 12,56% 758.300
12/07/2022 27,41 28,04 26,35 27,96 +2,12% 6,17% 697.500
11/07/2022 28,66 29,05 27,05 27,38 -4,86% 6,98% 674.400
08/07/2022 27,82 28,94 27,66 28,78 +0,21% 4,62% 502.900
07/07/2022 28,91 29,99 28,41 28,72 +0,53% 5,47% 854.400
06/07/2022 28,36 29,61 28,30 28,57 -0,07% 4,62% 992.500
05/07/2022 25,93 28,61 25,93 28,59 +7,89% 10,34% 956.100
01/07/2022 25,52 26,58 25,25 26,50 +4,58% 5,21% 555.800
30/06/2022 23,84 25,43 23,65 25,34 +3,81% 7,47% 889.000
29/06/2022 24,61 24,61 23,82 24,41 -0,04% 3,21% 451.700
28/06/2022 25,45 25,66 23,88 24,42 -3,52% 6,99% 518.200
27/06/2022 25,77 25,81 24,53 25,31 -0,94% 4,97% 601.500
24/06/2022 25,00 26,09 23,93 25,55 +2,28% 8,62% 1.867.300
23/06/2022 23,92 24,98 23,68 24,98 +6,21% 5,43% 888.200
22/06/2022 22,71 24,29 22,43 23,52 -0,17% 8,19% 661.300
21/06/2022 22,11 24,43 22,00 23,56 +6,99% 11,01% 1.078.700
17/06/2022 20,88 22,54 20,88 22,02 +6,27% 7,95% 2.283.300
16/06/2022 20,55 21,36 20,31 20,72 -4,34% 5,11% 805.800
15/06/2022 20,62 22,26 20,53 21,66 +5,04% 8,37% 782.700
14/06/2022 19,89 20,76 19,21 20,62 +4,30% 7,77% 710.900
13/06/2022 21,63 22,08 19,48 19,77 -12,21% 12,04% 760.600
10/06/2022 22,76 23,11 21,59 22,52 -2,68% 6,68% 989.400
09/06/2022 23,36 24,05 23,03 23,14 -2,03% 4,37% 671.800
08/06/2022 23,10 24,08 23,09 23,62 +1,85% 4,29% 705.900
07/06/2022 22,09 23,40 22,09 23,19 +3,80% 5,93% 703.800
06/06/2022 22,75 23,00 21,55 22,34 -0,76% 6,37% 848.800
03/06/2022 20,47 23,10 20,42 22,51 +9,54% 13,09% 1.480.900